Posted by Michael Wonder on 17 Sep 2021
BridgeBio Pharma receives FDA fast track designation for investigational therapy for the treatment of limb-girdle muscular dystrophy type 2i (LGMD2i)
15 September 2021 - If successful, BridgeBio's drug could be the first approved therapy for patients with LGMD2i.
BridgeBio Pharma today announced that the United States FDA granted fast track designation for the investigation of BBP-418 as a treatment option for limb-girdle muscular dystrophy type 2i (LGMD2i).
